BACKGROUND: @entity3119 ( @entity3119 ) is a @entity102 associated with substantial morbidity; it often requires long-term medication. The best-studied therapeutic agent in the treatment of this disorder is the tricyclic antidepressant @entity8991 . Since other tricyclic antidepressants appear to lack efficacy in @entity3119 , that of @entity8991 has been linked to its potent effects on @entity750 . Consequently, agents that selectively inhibit @entity750 reuptake have been the focus of several large-scale, placebo-controlled studies of @entity3119 . Their efficacy in @entity3119 is the focus of our review. DATA SOURCES: MEDLINE search (1966 to present) of @entity3119 treatment with @entity8991 or SSRI antidepressant medication using the key words @entity3119 , @entity750 reuptake inhibitors, @entity8991 , and pharmacology. STUDY FINDINGS: The selective @entity750 reuptake inhibitors @entity905 , @entity3756 , @entity3755 , and @entity903 have, in separate multicenter trials, demonstrated efficacy and tolerability in the treatment of @entity3119 . In contrast, @entity8991 , though efficacious, is often associated with substantial adverse events, particularly anticholinergic side effects. While 2 recent meta-analyses support the superior efficacy of @entity8991 over selective @entity750 reuptake inhibitors in the treatment of @entity3119 , 5 of 6 head-to-head comparisons of either @entity905 or @entity3755 versus @entity8991 have found similar efficacy but a lower incidence of side effects with the selective @entity750 reuptake inhibitor. A recently completed multicenter, 12-week, double-blind trial of @entity903 versus @entity8991 versus placebo showed @entity903 to be as effective as @entity8991 . With significantly fewer dropouts due to adverse effects than @entity8991 , @entity903 was also associated with superior tolerability. CONCLUSION: The suggestion that selective @entity750 reuptake inhibitors possess efficacy similar to that of @entity8991 , but have a superior side effect profile, may have important implications for @entity1 with @entity3119 who require long-term treatment.

A review of the efficacy of selective @entity750 reuptake inhibitors in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8991 :: ('MESH:D002997', 'Chemical') :: ['clomipramine'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity3755 :: ('MESH:D016666', 'Chemical') :: ['fluvoxamine'] @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illness'] @entity3756 :: ('MESH:D020280', 'Chemical') :: ['sertraline'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity3119 :: ('MESH:D009771', 'Disease') :: ['obsessive-compulsive disorder', 'Obsessive-compulsive disorder', 'OCD']
@entity3119 :: (MESH:D009771,Disease) :: ['obsessive-compulsive disorder']
